Table 2.
Serial CTC counts and outcomes by patient
| Pat. # | Sex, age at time of first CTC measurement, yr | MIFC primary tumor size, mm | MIFC Invasion | N and M status; other disease |
CTC count, cells/7.5 mL blood Stimulateda
serum Tg, μg/L Time post-last surgery |
Treatment and outcome at latest follow-up | |||
| 1 mo | 6 mos | 12 mos | 18 mos | ||||||
| 1 | F, 51 | 20 | C+V+ | NxM0 | 9 0.9 |
0 UD |
ND UD |
0 ND |
TT; 1 RAIT x 1.85 GBq; NED at 23 months |
| 2 | F, 29 | 25 | C+ | N0M0 | 3 1.9 |
0 1.4 |
0 0.4 |
0 ND |
TT; NED at 20 months |
| 3 | F, 77 | 6 | C+V+ | N0M0; colon cancer | 0 818 |
0 5.7 |
0 UD |
0 ND |
TT; 1 RAIT x 1.85 GBq; NED at 20 months |
| 4 | F, 46 | 50 | C+V+ | N0M0 | 3 2.3 |
0 2.1 |
0 2.0 |
0 ND |
TT; 1 RAIT x 1.11 GBq; NED at 17 months |
| 5 | M, 28 | 50 | C+V+ | N0M0 | 4 10 |
0 UD |
0 UD |
0 ND |
TT; 1 RAIT x 2.55 GBq; NED at 19 months |
| 6 | F, 37 | 12 | C+ | N0M0 | 0 15 |
0 0.3 |
0 1.3 |
0 ND |
Lob; NED at 39 months |
| 7 | F, 66 | 12 | C+ | NxM0 | 4 1.3 |
0 1 |
0 1 |
0 ND |
TT; NED at 18 months |
| 8 | F, 61 | 25 | C+ | NxM0 | 5 4.6 |
ND 0.6 |
ND 0.4 |
ND ND |
TT; NED at 50 months |
| 9 | F, 36 | 55 | C+V+ | NxM0 | 0 10 |
0 11 |
0 0.3 |
0 ND |
TT; 1 RAIT x 1.85 GBq; NED at 17 months |
| 10 | F, 47 | 60 | C+ | NxM0 | 0 0.4 |
0 UD |
0 UD |
0 ND |
TT; 1 RAIT x 1.85 GBq; NED at 14 months |
| 11 | M, 42 | 55 | C+ | N1aM0 | 0 4.7 |
0 ND |
0 ND |
0 ND |
TT; 1 RAIT x 3.3 GBq; NED at 4 months |
| 12 | F, 29 | 20 | C+ | NxM0 | 0 1.1 |
0 ND |
0 ND |
0 ND |
TT; 1 RAIT x 1.85 GBq; NED at 5 months |
| 13 | M, 61 | 25 | C+ | NxM0 | 0 1.7 |
0 ND |
0 ND |
0 ND |
TT; 1 RAIT x 1.85 GBq; NED at 6 months |
| 14 | F, 52 | 55 | C+V+ | NxM0 | 0 11.3 |
0 ND |
0 ND |
0 ND |
TT; NED at 3 months |
| 15 | F, 36 | 33 | None | N0M0; FTUMP | 1 35 |
0 20 |
0 0.2 |
0 ND |
CT2; 1 RAIT x 1.11 GBq; NED at 20 months |
| 16 | M, 37 | 13 | None | NxM0; FTUMP | 0 12 |
0 13 |
0 13 |
0 ND |
TT; NED at 18 months |
| 17 | F, 22 | 17 | None | NxM0; FTUMP | 2 30 |
0 1.1 |
0 0.7 |
0 ND |
CT2; NED at 17 months |
| 18 | F, 45 | 45 | None | N0M0; Hürthle cell adenoma with follicular pattern | 13 14.7 |
2 2.3 |
0 1.1 |
ND ND |
TT; NED at 19 months |
| 19 | F, 75 | 55 | C+EV+ | N0M1 (diffuse interstitial lung) | 5 158 |
2 101 |
1 2.5 |
1 ND |
TT, L; 1 RAIT x 6.3 GBq; PerD at 21 months |
| 20 | F, 34 | 14 | C+EV+ | NxM0; history of breast cancer | 0 16.6 |
0 13.6 |
0 0.4 |
0 ND |
TT; NED at 20 months |
| 21 | F, 39 | 10 | C+EV+ | NxM0 | 3 0.6 |
0 UD |
0 UD |
0 ND |
TT; 1 RAIT x 1.85 GBq; at 18 months |
| 22 | F, 67 | 38 | C+EV+ | NxM0 | 0 1.6 |
0 ND |
0 ND |
0 ND |
TT; NED at 3 months |
| 23 | F, 69 | 90 | C+EV+ | NxM0 | 7 1.5 |
ND ND |
ND ND |
ND ND |
TT; NED at 1 month |
| 24 | F, 35 | 54 | C+EV+ (right lobe) | N1bM0; PDTC (left lobe) | 7 882 |
5 145 |
2 51 |
2 ND |
TT, L; 3 RAITs totaling 10.2 GBq; PerD at 19 months |
| 25 | F, 60 | 24 | C+ (right lobe) | NxM0; PTC (left lobe) | 0 0.2 |
0 UD |
0 UD |
0 ND |
TT; 1 RAIT x 2.38 GBq; NED at 18 months |
| 26 | F, 61 | 3 | C+ (right lobe) | NxM0; MTC (left lobe) | 0 0.5 |
0 0.3 |
0 UD |
0 ND |
TT; NED at 18 months |
The 6-month, 12-month, and 18-month CTC and Tg tests were performed within 1 month before or after the putative testing time. To convert GBq into mCi, divide by 0.037. Due to rounding, percentages may not add to 100%.
C+, capsular invasion; CT2, completion thyroidectomy, total of 2 surgeries; EV+, extensive vascular invasion (>4 or “large” number of vessels invaded); FTUMP, follicular tumor of unknown malignant potential; L, lymphadenectomy; Lob, lobectomy; MIFC, minimally invasive thyroid carcinoma; MTC, medullary thyroid carcinoma; ND, not done; NED, no evidence of disease according to physical examination, serum Tg and TgAb, ultrasonography, and whole-body scintigraphy; PDTC, poorly differentiated thyroid carcinomal; PerD, persistent disease; PTC, papillary thyroid carcinoma; RAIT, radioiodine therapy; Tg, thyroglobulin; TT, total thyroidectomy; UD, undetectable (<0.04 μg/L); V+, vascular invasion; WIFC, widely invasive follicular thyroid carcinoma.
All Tg testing was performed following ≥2 weeks of thyroid hormone withdrawal, with serum thyrotropin >40 mIU/L.